{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:40:06Z","timestamp":1761486006611},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/mjt.0b013e3182a32e0e","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T14:04:59Z","timestamp":1401977099000},"page":"e583-e587","source":"Crossref","is-referenced-by-count":13,"title":["A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma"],"prefix":"10.1097","volume":"23","author":[{"given":"Kezban Nur","family":"Pilanc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiz","family":"Elb\u00fcken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7etin","family":"Ordu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fclistan","family":"K\u00f6ksal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Hakan","family":"Tekelio\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerem","family":"Okutur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00fcha","family":"G\u00f6ksel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00dclk\u00fchan","family":"K\u00f6ksal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tark","family":"Ak\u00e7al","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Co\u015fkun","family":"Tecimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-34-20210202","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10456-004-3149-y","article-title":". The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.","volume":"7","author":"Osusky","year":"2004","journal-title":"Angiogenesis"},{"key":"R2-34-20210202","first-page":"471","article-title":". SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.","volume":"2","author":"Abrams","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"R3-34-20210202","first-page":"327","article-title":". In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokineticpharmacodynamic relationship.","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R4-34-20210202","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","article-title":". SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.","volume":"20","author":"Murray","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"R5-34-20210202","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":". SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.","volume":"101","author":"OFarrell","year":"2003","journal-title":"Blood"},{"key":"R6-34-20210202","first-page":"4009","article-title":". SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.","volume":"63","author":"Schueneman","year":"2003","journal-title":"Cancer Res"},{"key":"R8-34-20210202","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1210\/jc.2005-2845","article-title":". An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RETpapillary thyroid cancer kinases.","volume":"91","author":"Kim","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-34-20210202","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","article-title":". Food and Drug Administration drug approval summary: sunitinib malate fort he treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.","volume":"12","author":"Rock","year":"2007","journal-title":"Oncologist"},{"key":"R10-34-20210202","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":". Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"R11-34-20210202","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy.","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"R12-34-20210202","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1158\/1078-0432.CCR-06-2254","article-title":". Targeting von Hippel-Lindau pathway in renal cell carcinoma.","volume":"12","author":"Patel","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R13-34-20210202","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/annonc\/mdp291","article-title":"Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib.","volume":"21","author":"Blay","year":"2010","journal-title":"Ann Oncol"},{"key":"R14-34-20210202","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":". Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"R15-34-20210202","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00280-008-0814-7","article-title":". Acute hepatic failure following monotherapy with sunitinib for ovarian cancer.","volume":"63","author":"Taran","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"R16-34-20210202","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1592\/phco.28.8.1066","article-title":"Sunitinib-related fulminant hepatic failure: case report and review of the literature.","volume":"28","author":"Mueller","year":"2008","journal-title":"Pharmacotherapy"},{"key":"R17-34-20210202","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.neurol.2008.03.007","article-title":". Posterior reversible encephalopathy syndrome during sunitinib therapy.","volume":"164","author":"Cumurciuc","year":"2008","journal-title":"Rev Neurol (Paris)"},{"key":"R18-34-20210202","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1080\/10428190701509822","article-title":". Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy.","volume":"48","author":"Nott","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R19-34-20210202","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":". Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R20-34-20210202","first-page":"S41","article-title":". Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.","volume":"1","author":"Kollmannsberger","year":"2007","journal-title":"Can Urol Assoc J"},{"key":"R21-34-20210202","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":". Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"key":"R22-34-20210202","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/1097-0142(20000901)89:5<1076::AID-CNCR17>3.0.CO;2-M","article-title":"Renal cell carcinoma to the pancreas in surgical pathology material: a clinicopathologic study of 21 cases with a review of the literature.","volume":"89","author":"Thompson","year":"2000","journal-title":"Cancer"},{"key":"R23-34-20210202","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1091-255X(01)80060-3","article-title":". Renal cell carcinoma metastatic to the pancreas: results of surgical management.","volume":"5","author":"Sohn","year":"2001","journal-title":"J Gastrointest Surg"},{"key":"R24-34-20210202","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s00268-005-0464-4","article-title":". Surgical treatment of metastatic tumors to the pancreas: a single center experience and review of the literature.","volume":"30","author":"Crippa","year":"2006","journal-title":"World J Surg"},{"key":"R25-34-20210202","first-page":"2414","article-title":"Solitary metastatic tumors to the pancreas: a case report and review of the literature.","volume":"91","author":"Robbins","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"R26-34-20210202","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0039-6109(05)70143-2","article-title":"Pancreatic cancer: the bigger picture.","volume":"81","author":"Cooperman","year":"2001","journal-title":"Surg Clin North Am"},{"key":"R27-34-20210202","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s005340050138","article-title":". Results of duedenopancreatectomy for solitary pancreatic metastasis from renal cell carcinoma.","volume":"6","author":"Tuech","year":"1999","journal-title":"J Hepatobiliary Pancreatic Surg"},{"key":"R28-34-20210202","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1200\/JCO.1998.16.6.2261","article-title":". Resection of metastatic renal cell carcinoma.","volume":"16","author":"Kavolius","year":"1998","journal-title":"J Clin Oncol"},{"key":"R29-34-20210202","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jjco\/hyq164","article-title":". Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.","volume":"41","author":"Matsumoto","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"R30-34-20210202","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1345\/aph.1Q038","article-title":". Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.","volume":"45","author":"Lee","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R31-34-20210202","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1463-1326.2009.01054.x","article-title":"Ammonia toxicity and its prevention in inherited defects of the urea cycle.","volume":"11","author":"Walker","year":"2009","journal-title":"Diabetes Obes Metab"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e3182a32e0e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:38:19Z","timestamp":1620963499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201603000-00034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3182a32e0e","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}